Yasuhito Nagamoto1, Kazuo Takayama2, Kazuo Ohashi3, Ryota Okamoto1, Fuminori Sakurai4, Masashi Tachibana5, Kenji Kawabata6, Hiroyuki Mizuguchi7. 1. Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan; Laboratory of Hepatocyte Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan. 2. Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan; Laboratory of Hepatocyte Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan; The Keihanshin Consortium for Fostering the Next Generation of Global Leaders in Research (K-CONNEX), Kyoto University, Kyoto 606-8302, Japan. 3. Laboratory of Drug Development and Science, Osaka University, Osaka 567-0085, Japan; iPS Cell-Based Projects on Cell Transplantation and Cell Dynamics, Osaka University, Osaka 567-0085, Japan. 4. Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan; Laboratory of Regulatory Sciences for Oligonucleotide Therapeutics, Osaka University, Osaka 567-0085, Japan. 5. Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan. 6. Laboratory of Stem Cell Regulation, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka 567-0085, Japan. 7. Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan; Laboratory of Hepatocyte Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan; iPS Cell-Based Research Project on Hepatic Toxicity and Metabolism, Clinical Drug Development Unit, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan; Global Center for Medical Engineering and Informatics, Osaka University, Osaka 565-0871, Japan. Electronic address: mizuguch@phs.osaka-u.ac.jp.
Abstract
BACKGROUND & AIMS: Hepatocyte transplantation is one of the most attractive approaches for the treatment of patients with liver failure. Because human induced pluripotent stem cell-derived hepatocyte-like cells (iPS-HLCs) can be produced on a large scale and generated from a patient with liver failure, they are expected to be used for hepatocyte transplantation. However, when using conventional transplantation methods, i.e., intrasplenic or portal venous infusion, it is difficult to control the engraftment efficiency and avoid unexpected engraftment in other organs because the transplanted cells are delivered into blood circulation before their liver engraftment. METHODS: In this study, to resolve these issues, we attempted to employ a cell sheet engineering technology for experimental hepatocyte transplantation. The human iPS-HLC sheets were attached onto the liver surfaces of mice with liver injury. RESULTS: This method reduced unexpected engraftment in organs other than the liver compared to that by intrasplenic transplantation. Human albumin levels in the mice with human iPS-HLC sheets were significantly higher than those in the intrasplenically-transplanted mice, suggesting the high potential for cell engraftment of the sheet transplantation procedure. In addition, human iPS-HLC sheet transplantation successfully ameliorated lethal acute liver injury induced by the infusion of carbon tetrachloride (CCl4). Moreover, we found that the hepatocyte growth factor secreted from the human iPS-HLC sheet played an important role in rescuing of mice from acute hepatic failure. CONCLUSIONS: Human iPS-HLC sheet transplantation would be a useful and reliable therapeutic approach for a patient with severe liver diseases.
BACKGROUND & AIMS: Hepatocyte transplantation is one of the most attractive approaches for the treatment of patients with liver failure. Because human induced pluripotent stem cell-derived hepatocyte-like cells (iPS-HLCs) can be produced on a large scale and generated from a patient with liver failure, they are expected to be used for hepatocyte transplantation. However, when using conventional transplantation methods, i.e., intrasplenic or portal venous infusion, it is difficult to control the engraftment efficiency and avoid unexpected engraftment in other organs because the transplanted cells are delivered into blood circulation before their liver engraftment. METHODS: In this study, to resolve these issues, we attempted to employ a cell sheet engineering technology for experimental hepatocyte transplantation. The human iPS-HLC sheets were attached onto the liver surfaces of mice with liver injury. RESULTS: This method reduced unexpected engraftment in organs other than the liver compared to that by intrasplenic transplantation. Human albumin levels in the mice with human iPS-HLC sheets were significantly higher than those in the intrasplenically-transplanted mice, suggesting the high potential for cell engraftment of the sheet transplantation procedure. In addition, human iPS-HLC sheet transplantation successfully ameliorated lethal acute liver injury induced by the infusion of carbon tetrachloride (CCl4). Moreover, we found that the hepatocyte growth factor secreted from the human iPS-HLC sheet played an important role in rescuing of mice from acute hepatic failure. CONCLUSIONS:Human iPS-HLC sheet transplantation would be a useful and reliable therapeutic approach for a patient with severe liver diseases.
Authors: Clara T Nicolas; Raymond D Hickey; Kari L Allen; Zeji Du; Rebekah M Guthman; Robert A Kaiser; Bruce Amiot; Aditya Bansal; Mukesh K Pandey; Lukkana Suksanpaisan; Timothy R DeGrado; Scott L Nyberg; Joseph B Lillegard Journal: Surgery Date: 2018-06-06 Impact factor: 3.982
Authors: Hongxia Liang; Ke Huang; Teng Su; Zhenhua Li; Shiqi Hu; Phuong-Uyen Dinh; Emily A Wrona; Chen Shao; Li Qiao; Adam C Vandergriff; M Taylor Hensley; Jhon Cores; Tyler Allen; Hongyu Zhang; Qinglei Zeng; Jiyuan Xing; Donald O Freytes; Deliang Shen; Zujiang Yu; Ke Cheng Journal: ACS Nano Date: 2018-06-26 Impact factor: 15.881
Authors: Clara T Nicolas; Raymond D Hickey; Harvey S Chen; Shennen A Mao; Manuela Lopera Higuita; Yujia Wang; Scott L Nyberg Journal: Stem Cells Date: 2016-10-02 Impact factor: 6.277